NantKwest (NASDAQ: NK) stock surged 23.14% to $18.2 in the extended hour’s section. Before that during the regular session stock was down -7.57% to close at $14.78. NK shares price is currently trading at a distance of 37.21% from its 50-days Simple Moving Average.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
An innovative, clinical-stage, immunotherapy company, NantKwest (NASDAQ: NK) harnesses the innate immune system’s power to treat cancer and infectious diseases. NK Cells NantKwest is the leader in producing clinical dose natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancerous cells as well as virally-infected cells.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
What happened lately…
NantKwest, Inc. (NASDAQ: NK), a leading company in cellular medicines, and ImmunityBio, Inc., which is a privately held immunotherapy company revealed that the median survival rates for patients with advanced metastatic pancreatic cancer which is currently untreated have more than doubled compared to historical survival rates.
PD L1 t-haNK protocol data from NantKwest, Inc. (NASDAQ: NK) shows median survival rates more than doubled those of patients with advanced metastatic pancreatic cancer for which no FDA-approved treatment exists. These trials, derived from the original Cancer Moonshot hypothesis and the exploratory QUILT trials in 2017, suggest that survival rates can be improved by orchestrating natural killer and T-cell therapy without high-dose chemotherapy.
Early Cancer Moonshot trials combined cell therapy and immunotherapy from several companies, including ImmunityBio, NantKwest, Celgene, and Pfizer. The problem explored the hypothesis that cancer cells could be eradicated by activating the patient’s immune system rather than high-dose chemotherapy. In multiple QUILT clinical trials investigating the combination of cell therapy, immunostimulating antibodies, adenovirus-based cancer vaccines, and low-dose chemotherapy between 2017 and 2020, preliminary results have proved the median survival rate for patients with metastatic pancreatic cancer can increase threefold. Based on data from these trials, ImmunityBio is conducting a three-cohort pivotal trial (QUILT 88) in metastatic pancreatic cancer.
Analysts may see many potentials in the biotech stocks but failing clinical trials could happen if the biotechs do well in tests. There are risks associated with investing in biotech stocks, including companies running out of money and needing to pay for clinical studies, complete regulatory filings, and bring new drugs to market.